We envision that ATF activation will provide superior control of IFN-γ activity against cancer cell lines, particularly in the context of co-administering IFN-γ with a chemotherapy agent that have previously been shown to increase patient survival (Windbichler et al., 2000). Here, IFNG is linked to cancer.